ALBUQUERQUE, N.M.--(BUSINESS WIRE)--SolaranRx, Inc. has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, SRX-1177, to treat metastatic melanoma.
SolaranRX CEO Les Stewart will present at Informa’s Therapeutic Area Partnerships meeting at the Hyatt Regency in Boston on Thursday, November 20 within Track 3 (Oncology). He will discuss SRX-1177, a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors, which are over-expressed in about 80 percent of melanoma cells. SRX-1177 can be used to identify melanoma patients with MC1 receptors. Those patients can then be injected with therapeutic doses of SRX-1177 to deliver targeted radiation, while minimizing the impact on healthy cells. This merger of therapy and diagnostics creates a unique theranostic product for metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.
